Cargando…
Varespladib (LY315920) Appears to Be a Potent, Broad-Spectrum, Inhibitor of Snake Venom Phospholipase A2 and a Possible Pre-Referral Treatment for Envenomation
Snakebite remains a neglected medical problem of the developing world with up to 125,000 deaths each year despite more than a century of calls to improve snakebite prevention and care. An estimated 75% of fatalities from snakebite occur outside the hospital setting. Because phospholipase A2 (PLA2) a...
Autores principales: | Lewin, Matthew, Samuel, Stephen, Merkel, Janie, Bickler, Philip |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5037474/ https://www.ncbi.nlm.nih.gov/pubmed/27571102 http://dx.doi.org/10.3390/toxins8090248 |
Ejemplares similares
-
Varespladib (LY315920) and Methyl Varespladib (LY333013) Abrogate or Delay Lethality Induced by Presynaptically Acting Neurotoxic Snake Venoms
por: Gutiérrez, José María, et al.
Publicado: (2020) -
Structural basis for phospholipase A(2)-like toxin inhibition by the synthetic compound Varespladib (LY315920)
por: Salvador, Guilherme H. M., et al.
Publicado: (2019) -
Action of Varespladib (LY-315920), a Phospholipase A(2) Inhibitor, on the Enzymatic, Coagulant and Haemorrhagic Activities of Lachesis muta rhombeata (South-American Bushmaster) Venom
por: Gutierres, Pamella G., et al.
Publicado: (2022) -
Coagulotoxic Cobras: Clinical Implications of Strong Anticoagulant Actions of African Spitting Naja Venoms That Are Not Neutralised by Antivenom but Are by LY315920 (Varespladib)
por: Bittenbinder, Mátyás A., et al.
Publicado: (2018) -
Varespladib in the Treatment of Snakebite Envenoming: Development History and Preclinical Evidence Supporting Advancement to Clinical Trials in Patients Bitten by Venomous Snakes
por: Lewin, Matthew R., et al.
Publicado: (2022)